{"id":461267,"date":"2026-02-11T02:11:16","date_gmt":"2026-02-11T02:11:16","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/461267\/"},"modified":"2026-02-11T02:11:16","modified_gmt":"2026-02-11T02:11:16","slug":"physician-highlights-health-benefits-of-glp-1-drugs-that-go-beyond-weight-loss-osteoarthritis-to-cardiovascular-events","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/461267\/","title":{"rendered":"Physician highlights health benefits of GLP-1 drugs that go beyond weight loss: Osteoarthritis to cardiovascular events"},"content":{"rendered":"

GLP-1 drugs like Ozempic <\/a>and Wegovy, for the longest time, have been thought to have benefits that are dependent on weight loss. However, a new study shows that many of its health benefits have little to do with weight loss.<\/p>\n

\"AA new study reveals GLP-1 drugs like semaglutide offer significant health benefits beyond weight loss. (Shutterstock)<\/p>\n

Also Read | Helen at 86 shares 4 balance, strength exercises that prove \u2018movement has no age limit\u2019; reveals why she works out<\/a><\/p>\n

On February 10, Eric Topol, a physician-scientist and founder and director of Scripps Research Translational Institute, highlighted the many benefits of GLP-1 drugs by sharing a February 9 study <\/a>\u2013 \u2018Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism.\u2019<\/p>\n

Benefits of GLP-1 drugs beyond weight loss<\/p>\n

Highlighting the findings of the study, Eric wrote, \u201cWe used to think that the benefit of GLP-1 drugs (like Ozempic) was dependent on weight loss. Now we know so many health benefits<\/a> have little to do with that.” He added, “Independent of weight loss, semaglutide (Ozempic) improves knee arthritis by cartilage restoration, in both the mouse model and a small randomised clinical trial.\u201d<\/p>\n

Summarising the study’s findings, Eric highlighted the many benefits of taking GLP-1 drugs. According to him, these drugs also help in osteoarthritis (OA), heart outcomes, kidney health, and liver health.<\/p>\n

In OA, the GLP-1 drugs were found to affect cartilage restoration in a mouse model (a laboratory mouse used to study aspects of human physiology or disease) and a pilot randomised clinical trial (a small version of the main study).<\/p>\n

Moreover, it found that GLP-1 therapy altered cellular metabolism in cartilage cells, shifting them away from glycolysis (a less efficient energy-generating pathway) toward oxidative metabolism (a more efficient one).<\/p>\n

Impact on the liver, heart and kidney<\/p>\n

Meanwhile, in heart outcomes, the study found that 66% of the reduction in major adverse cardiovascular events (MACE) was unrelated to weight loss; arterial inflammation was reduced immediately. As for kidney outcomes, it found a 100% effect independent of weight loss and direct interaction with GLP-1 receptors in the kidney, reduced protein excretion.<\/p>\n

Lastly, in the liver, the study found that 50-70% of the benefit in MASH is unrelated to weight loss and reduced lipotoxicity, and liver enzymes improved before any weight loss. Meanwhile, metabolic dysfunction-associated steatohepatitis (MASH) is a form of liver inflammation and damage caused by a buildup of fat in the liver.<\/p>\n

Moreover, these findings expand the potential use of semaglutide beyond metabolic diseases to joint degenerative conditions such as osteoarthritis and other health conditions.<\/p>\n

Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.<\/p>\n","protected":false},"excerpt":{"rendered":"GLP-1 drugs like Ozempic and Wegovy, for the longest time, have been thought to have benefits that are…\n","protected":false},"author":2,"featured_media":461268,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[38153,97,215138,132835,21672,102396,249],"class_list":{"0":"post-461267","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-glp-1-drugs","9":"tag-health","10":"tag-heart-outcomes","11":"tag-kidney-health","12":"tag-liver-health","13":"tag-osteoarthritis","14":"tag-ozempic"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/461267","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=461267"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/461267\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/461268"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=461267"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=461267"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=461267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}